Postgrad LIVE! Study Fairs

Birmingham | Edinburgh | Liverpool | Sheffield | Southampton | Bristol

University of Birmingham Featured PhD Programmes
University College London Featured PhD Programmes
University of Oxford Featured PhD Programmes
Imperial College London Featured PhD Programmes
Birkbeck, University of London Featured PhD Programmes
"monoclonal" AND "antibod…×
10 miles

monoclonal antibodies PhD Projects, Programs & Scholarships

We have 10 monoclonal antibodies PhD Projects, Programs & Scholarships

  • "monoclonal" AND "antibodies" ×
  • clear all
Order by 
Showing 1 to 10 of 10
  Development of novel cell-based techniques for evaluating the effector functions of therapeutic antibodies
  Dr A Watts
Application Deadline: 16 December 2018
Supervisory Team. Lead supervisor. Dr Andrew Watts, Department of Pharmacy & Pharmacology, University of Bath. Co-supervisors. Prof David Tosh and Dr Jody Mason, Department of Biology & Biochemistry, University of Bath.
  Dissecting the neutralising antibody response to the porcine reproductive and respiratory syndrome virus to identify novel vaccine targets
  Prof R Owens, Dr S Graham, Dr J Grimes, Prof John Hammond
Application Deadline: 25 January 2019
Porcine reproductive and respiratory syndrome (PRRS) is the most important infectious disease affecting the global pig industry.
  Cryptosporidium parvum – B-cells as a route to control
  Dr R Flynn
Application Deadline: 11 January 2019
Cryptosporidium parvum infection presents a major threat to calf health and survival as a global cause of enteric disease. Calves under the age of 2 months are 41 times more likely to shed oocysts in comparison with animals aged 4 months or above.
  Biological significance, predictive value and targeting of the HER family members in pancreatic cancer
  Prof H Modjtahedi
Applications accepted all year round
Despite major advances in imaging technologies, surgery, chemotherapy, radiotherapy and targeted therapy of cancer in the last few decades, pancreatic cancer remains as one of the most aggressive and fatal types of human cancer.
  (BBSRC DTP CASE) Native Mass Spectrometry approaches for Electron and Photon mediated Top Down Sequencing of Biotherapeutics
  Prof P Barran, Dr B Bellina
Application Deadline: 31 January 2019
In this project we propose to develop electron and photon mediated top-down sequencing methods to analyse recombinant biological therapeutics including monoclonal antibodies (mAbs) and adeno-associated viral (AAV) vectors.
  Airway, Liver and Muscle Gene Transfer to Create Therapeutic Protein Factories: utilising experience of in vivo gene transfer and/or in vivo gene editing to understand and manipulate the factors required for effective expression and secretion of therapeutic proteins
  Dr S Hyde, Dr D Gill
Application Deadline: 11 January 2019
We are focusing on strategies to deliver therapeutics via in vivo delivery of gene transfer vectors to generate ectopic “protein factories” capable of secreting therapeutic proteins into both the lung lumen and the systemic circulation.
  Immune Development in a Piglet Model of Environmental Enteric Dysfunction
  Dr M Lewis, Prof G Gibson
Applications accepted all year round
Summary. Environmental enteric dysfunction (EED) affects 200 million children in low- and middle-income countries and has extremely detrimental consequences for long-term health.
  Tetraspanin structure and function
  Dr L J Partridge
Applications accepted all year round
The tetraspanins are a diverse, conserved family of eukaryotic membrane proteins. Their principal feature is the ability to form dynamic multi-molecular assemblies in cell membranes known as tetraspanin enriched microdomains (TEM).
  High-performance glycoengineering of IgE antibodies
  Dr G Wagner, Dr S Karagiannis
Application Deadline: 11 January 2019
Immunoglobulin E (IgE)-based antibodies are currently under investigation as novel immunotherapeutics for the treatment of cancer [1].
  PhD in Infection & Immunity - Modifying human cytomegaloviruses to drive expansion of effector natural killer and cytotoxic T cells
  Dr E Wang, Dr R Stanton
Application Deadline: 27 February 2019
Natural Killer (NK) cells and CD8+ cytotoxic T lymphocytes (CTL) are immune cells known to kill cancerous and virus-infected cells and are being used to treat forms of these diseases.
Show 10 15 30 per page
  • 1


FindAPhD. Copyright 2005-2018
All rights reserved.